1st July 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

JB Chemicals receives board clearance to pay Rs 98 crore for Dr Reddy's 4 brands

JB Chemicals & Pharmaceuticals announced that its board had authorized a plan to pay around Rs 98 crore to Dr Reddy’s Laboratories to buy four paediatric brands.

PCI to introduce the national pharmacy One Nation One Cadre guidelines

The Pharmacy Council of India (PCI) is considering implementing a guideline for the One Nation One Cadre system in order to standardise the pharmacy profession across the country.

Pharma major Bayer has its eyes set on the OTC (over the counter) sector in India

In July, Bayer India’s consumer health division will introduce a new product within the nutrition category. This follows the company’s recent launch of the new medicine Saridon Advance for severe headaches.

Research-Linked Incentive Scheme to Enhance Indian Pharmaceutical Market's Global Image

The Narendra Modi government is getting ready to introduce a “research-linked incentive scheme” with the goal of boosting India’s standing in the global pharmaceutical market on the innovation index.

Tislelizumab from Novartis shows promising survival outcomes in advanced esophageal cancer

As a first-line therapy for adult patients, tislelizumab plus chemotherapy significantly increased overall survival (OS), according to results from the Phase III RATIONALE 306 trial released on Thursday by Novartis.

Novartis announces a new manufacturing plant in Mumbai to produce generic cancer drugs

Novartis has opened a new production factory for generic oral cancer medications in Kalwe, Mumbai. The plant, which was constructed on a brownfield site, is equipped with effluent treatment systems to promote green manufacturing standards.

As per AstraZeneca, Imfinzi combination shows promise in a late-stage lung cancer trial

Imfinzi, a cancer drug by AstraZeneca, and chemotherapy when administered prior to surgery in patients with an aggressive form of lung cancer showed promise in a late-stage trial.